Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.
Treatment with Brukinsa (zanubrutinib) demonstrated better efficacy compared with Imbruvica (ibrutinib), as well as an improved overall safety and tolerability profile in patients with relapsed or ...
Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...
Gastrointestinal diseases are those that affect any section of the gastrointestinal tract, from the oesophagus to the rectum, and the accessory digestive organs liver, gall bladder and pancreas ...
Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...
Gastrointestinal illness outbreaks on Princess Cruises and Viking ships sickened nearly 150 people. Among 1,894 guests aboard Princess’ Coral Princess ship, 59 reported being ill during its ...
In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...
Although CAR T-cell treatment can lead to clinical remissions in patients with hematological malignancies, relapse rates ultimately remain high. Previous research has found that T memory stem cell ...
On World Cancer Day 2025, learn how cancer affects different age groups in India. Oncologists share insights on early detection, prevention, and the importance of regular screenings.